In simple words: The implanted material used to bulk up the urethra has become exposed within the urethra. This is the patient's first encounter for this issue.

Exposure of implanted urethral bulking agent into urethra, initial encounter.

Example 1: A 65-year-old female patient presents with urethral pain and discharge one year after receiving a urethral bulking agent injection for stress urinary incontinence. Examination reveals exposure of the bulking agent within the urethra. This is her first encounter for this complication., A 50-year-old male patient experiences discomfort and bleeding during urination several months after a urethral bulking procedure. Cystoscopy reveals exposure of the implanted bulking agent into the urethra. This is his initial encounter for this complication., A 70-year-old female with a history of stress urinary incontinence, treated with urethral bulking agent, presents to the urologist's office complaining of pain during intercourse. Upon examination, the physician determines exposure of the implanted bulking agent. This is the patient’s first visit with this complaint.

Documentation should include details of the initial bulking procedure, the present symptoms, physical exam findings confirming the exposure, and any diagnostic tests performed (e.g., cystoscopy). The chosen treatment plan and its rationale should also be documented.